ATE509097T1 - Gewinnung von rekombinantem menschlichem parainfluenzavirus typ 1 (hpivi) aus cdna - Google Patents

Gewinnung von rekombinantem menschlichem parainfluenzavirus typ 1 (hpivi) aus cdna

Info

Publication number
ATE509097T1
ATE509097T1 AT02799195T AT02799195T ATE509097T1 AT E509097 T1 ATE509097 T1 AT E509097T1 AT 02799195 T AT02799195 T AT 02799195T AT 02799195 T AT02799195 T AT 02799195T AT E509097 T1 ATE509097 T1 AT E509097T1
Authority
AT
Austria
Prior art keywords
hpivi
recombinant human
piv
cdna
recombinant
Prior art date
Application number
AT02799195T
Other languages
English (en)
Inventor
Brian Murphy
Peter Collins
Mario Skiadopoulos
Jason Newman
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Application granted granted Critical
Publication of ATE509097T1 publication Critical patent/ATE509097T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18611Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18622New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18611Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18641Use of virus, viral particle or viral elements as a vector
    • C12N2760/18643Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18611Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18661Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT02799195T 2001-11-21 2002-11-21 Gewinnung von rekombinantem menschlichem parainfluenzavirus typ 1 (hpivi) aus cdna ATE509097T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33196101P 2001-11-21 2001-11-21
PCT/US2002/037688 WO2003043587A2 (en) 2001-11-21 2002-11-21 Recovery of recombinant human parainfluenza virus type 1 (hpivi) from cdna

Publications (1)

Publication Number Publication Date
ATE509097T1 true ATE509097T1 (de) 2011-05-15

Family

ID=23296092

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02799195T ATE509097T1 (de) 2001-11-21 2002-11-21 Gewinnung von rekombinantem menschlichem parainfluenzavirus typ 1 (hpivi) aus cdna

Country Status (6)

Country Link
US (1) US7704509B2 (de)
EP (2) EP2100955A3 (de)
AT (1) ATE509097T1 (de)
AU (2) AU2002364121C1 (de)
CA (1) CA2467958A1 (de)
WO (1) WO2003043587A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050287540A1 (en) * 1995-09-27 2005-12-29 Murphy Brian R Production of attenuated negative stranded RNA virus vaccines from cloned nucleotide sequences
US8715922B2 (en) * 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
US20030232061A1 (en) * 2001-10-18 2003-12-18 Fouchier Ronaldus Adrianus Maria Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
NZ527221A (en) 2001-01-19 2006-09-29 Vironovative B A negative-sense single stranded RNA virus causing respiratory tract illness in susceptible mammals
JP4553588B2 (ja) 2002-02-21 2010-09-29 メディミューン,エルエルシー メタニューモウイルス(metapneumovirus)株と、ワクチン製剤でのおよび抗原配列発現用ベクターとしてのその使用
AU2003270824B2 (en) * 2002-09-18 2009-02-19 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Recovery of recombinant human parainfluenza virus type 2 (HPIV2) from cDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens
JP2007525178A (ja) 2003-04-25 2007-09-06 メッドイミューン バクシーンズ,インコーポレイティド メタニューモウイルス株、そのワクチン製剤における用途、抗原性配列の発現のためのベクターとしての用途、並びにウイルス増殖方法
JP2006524511A (ja) * 2003-04-25 2006-11-02 メッドイミューン バクシーンズ,インコーポレイティド メタニューモウイルス由来の異種抗原を含む組換えパラインフルエンザウイルス発現系およびワクチン
JP4976376B2 (ja) * 2005-04-08 2012-07-18 メディミューン,エルエルシー 哺乳動物メタニューモウイルスに対する抗体
US20070092871A1 (en) * 2005-10-20 2007-04-26 Combimatrix Corporation Microarray for pathogen identification
US20100330120A1 (en) * 2007-05-08 2010-12-30 Collins Peter L Human parainfluenza viruses having separated p and c genes
EP2069485A4 (de) * 2007-07-13 2011-05-25 Medimmune Llc Zubereitung von negativstrang-rna-viren mittels elektroporation
GB0719818D0 (en) * 2007-10-11 2007-11-21 Asterion Ltd Growth hormone fusion polypeptides
US20090186050A1 (en) * 2007-11-16 2009-07-23 Fouchier Ron A M Live attenuated metapneumovirus strains and their use in vaccine formulations and chimeric metapneumovirus strains
WO2010003032A2 (en) * 2008-07-01 2010-01-07 The Government Of The United States Of America, Represented By The Secretary, Department Of Health A Recombinant human parainfluenza type 1 viruses (hpiv1s) containing mutations in or deletion of the c protein are attenuated in african green monkeys and in ciliated human airway epithelial cells and are potential vaccine candidates for hpiv1
DK2702159T3 (en) 2011-04-28 2018-11-19 St Jude Childrens Res Hospital MODIFIED SENDAI VIRUS VACCINE AND IMAGE VECTOR
JP7020917B2 (ja) 2015-01-20 2022-02-16 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ キメラrsv/bpiv3 fタンパクを発現する組換えヒト/ウシパラインフルエンザウイルス3(b/hpiv3)およびその使用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US708395A (en) 1901-04-15 1902-09-02 Oscar Peterson Device for digging ditches.
US2177396A (en) 1936-04-18 1939-10-24 Borden Co Milk bottle
DE3224404A1 (de) 1982-06-30 1984-01-05 LuK Lamellen und Kupplungsbau GmbH, 7580 Bühl Reibungskupplung sowie verfahren zu deren montage
US4614197A (en) 1984-10-15 1986-09-30 Deere & Company Chaff spreading arrangement for a combine
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4763497A (en) 1986-09-03 1988-08-16 Clover Co., Ltd. Lock device for double sliding doors
US5938597A (en) 1995-05-04 1999-08-17 Stratbucker; Robert A. Electrocardiograph bioelectric interface system and method of use
DE69510207T3 (de) 1995-08-09 2007-02-15 Schweiz. Serum- & Impfinstitut Bern Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren
US6699476B1 (en) 1996-07-15 2004-03-02 Peter L. Collins Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
EP2112220A3 (de) 1996-07-15 2010-01-06 The Government of the United States of America, as represented by The Department of Health and Human Services Herstellung abgeschwächter Impfstoffe gegen das respiratorische Synzytialvirus aus geklonten Nukleotidsequenzen
AU7797798A (en) 1997-05-23 1998-12-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences
US6410023B1 (en) 1997-05-23 2002-06-25 United States Of America Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene
CA2378661A1 (en) 1999-07-09 2001-01-18 Alexander C. Schmidt Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines
MXPA01008108A (es) 1999-12-10 2004-11-12 Health Uso de virus de parainfluenza recombinante (pivs) como vectores para la proteccioncontra la infeccion y enfermedad provocadas por piv y otros patogenos humanos.
US8379398B2 (en) 2011-03-23 2013-02-19 Phoenix Contact Development & Manufacturing, Inc. DIN rail mountable base for process fieldbus redundant power conditioner

Also Published As

Publication number Publication date
EP1456398B1 (de) 2011-05-11
EP1456398A4 (de) 2006-09-27
WO2003043587A3 (en) 2004-04-22
CA2467958A1 (en) 2003-05-30
US7704509B2 (en) 2010-04-27
AU2002364121B2 (en) 2009-03-12
EP1456398A2 (de) 2004-09-15
AU2002364121C1 (en) 2010-02-18
WO2003043587A9 (en) 2011-06-09
EP2100955A2 (de) 2009-09-16
AU2009202359A1 (en) 2009-07-02
US20040142448A1 (en) 2004-07-22
WO2003043587A2 (en) 2003-05-30
EP2100955A3 (de) 2009-12-02
AU2002364121A1 (en) 2003-06-10

Similar Documents

Publication Publication Date Title
ATE509097T1 (de) Gewinnung von rekombinantem menschlichem parainfluenzavirus typ 1 (hpivi) aus cdna
WO2004027037A3 (en) RECOVERY OF RECOMBINANT HUMAN PARAINFLUENZA VIRUS TYPE 2 (HPIV2) FROM cDNA AND USE OF RECOMBINANT HPIV2 IN IMMUNOGENIC COMPOSITIONS AND AS VECTORS TO ELICIT IMMUNE RESPONSES AGAINST PIV AND OTHER HUMAN PATHOGENS
WO2001042445A3 (en) USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS
WO2005014626A3 (en) Recombinant human metapneumovirus and its use
ATE408693T1 (de) Attenuiertes human-bovines chimärisches parainfluenzavirus als impfstoff
WO2006096459A3 (en) Infectious, chimeric hepatitis c virus, methods of producing the same and methods of use thereof
BR0013195A (pt) Produção de vacinas de virus sincicial respiratório quimérico humano-bovino, atenuado
ATE442866T1 (de) Fusionsproteine aus mycobakterium tuberculosis
BRPI0309631A2 (pt) vacina tetravalente da dengue contendo uma trivial deleção de 30 nucleotídeos na utr-31' dos tipos de dengue 1,2,3,e 4, ou de vírus antigênicos quiméricos da dengue 1,2,3 e 4
WO2003048184A3 (en) Flavivirus ns1 subunit vaccine
BR0113577A (pt) Empacotamento de partìculas de replicon de vìrus de rna de filamento positivo
EP2263690A3 (de) Chimäre infektiöse DNS-Klone von Schweine-Circoviren und ihre Verwendung
CY1109036T1 (el) Εμβολιο περιλαμβανον εναν εξασθενημενο ιο πανωλης
BR0312173A (pt) Mólecula de cdna, molécula e sequência de cdna recombinante, vetor, processo de preparação de partìculas de vìrus do sarampo infeccioso, composição imunogênica, composição de vacina e vìrus mononegaviral recombinante
WO2007047938A3 (en) Influenza viruses able to infect canids, uses thereof
WO2003076591A8 (en) Compositions and methods for generating an immune response
ATE365206T1 (de) Verfahren zur entwicklung von einem hiv impfstoff
ATE461283T1 (de) Neue vollständige genomische rna des japanenzephalitis-virus, infektiöse jev cdna daraus und deren verwendung
WO2002027007A3 (en) Production of viral vectors
EP1613345A4 (de) Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320
WO2009051823A3 (en) Bacterial artificial chromosome containing feline herpes virus type 1 genome and uses thereof
DE602004018975D1 (de) Promotoren zur expression im modifizierten vacciniavirus ankara
ATE303821T1 (de) Neue vakzinformulierung aus dna-vakzine- inaktiviertem virus
WO2003049670A3 (en) Adjuvant formulations for bacterial and virus vaccines and method of making same
TH78124B (th) วัคซีนหน่วยย่อย ns1 ของเฟลวิไวรัส

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties